Ionis Community Update: Zilganersen Program

Written By Kristen Birkbeck

Ionis has shared a new community statement on the zilganersen program with several important updates:

  • Extended access for clinical trial participants through a new protocol amendment

  • New pivotal trial data presented at AAN 2026

  • FDA decision target remains September 22, 2026

  • Active work to advance global access through regional pharmaceutical partnerships

In response to our open letter, Ionis met with community and organizational leaders across multiple countries.

The voices of our AxD community are shaping this work.

Read the full statement here.

Kristen Birkbeck
Next

Loudoun Times Feature: The Cancelleri Family’s Story